International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia


1Division of Respirology, Department of Medicine, St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada
2Li Ka Shing Knowledge Institute, St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada
3Departments of Medicine, Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
4Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
5University of the Saarland, Medical Faculty, Homburg/Saar, Germany
6Department of Otorhinolaryngology, Holweide Hospital, Hospitals of the City of Cologne, Cologne, Germany
7Department of Radiology, University of Utah, Salt lake City, Utah.
8Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, USA
9Department of Surgery, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada
10Dept of Otolaryngology/Head & Neck Surgery, University of Toronto, Toronto, ON, Canada
11U.O di Gastroenterologia ed Endoscopia Digestiva, Ospedale Maggiore, Crema, Italy
12Portland VA Medical Center, HHT Center of Excellence, Dotter Interventional Institute, Oregon Health & Science University
13University of Lyon, Hospices Civils de Lyon, National reference center for rare pulmonary diseases, Lyon, France

Copyright Article author (or their employer) 2009. Produced by BMJ Publishing Group Ltd under licence.
Word count=5536

Key Words:
Guidelines
Hereditary hemorrhagic telangiectasia
Arteriovenous malformation
Telangiectasia
Epistaxis
Abstract
HHT is an autosomal dominant disease with an estimated prevalence of at least 1/5000 which can frequently be complicated by the presence of clinically significant arteriovenous malformations in the brain, lung, gastrointestinal tract and liver. HHT is under-diagnosed and families may be unaware of the available screening and treatment, leading to unnecessary stroke and life-threatening hemorrhage in children and adults. The goal of this international HHT guidelines process was to develop evidence-informed consensus guidelines regarding the diagnosis of HHT and the prevention of HHT-related complications and treatment of symptomatic disease. The overall guidelines process was developed using the AGREE framework, using a systematic search strategy and literature retrieval with incorporation of expert evidence in a structured consensus process where published literature was lacking. The Guidelines Working Group included experts (clinical and genetic) from eleven countries, in all aspects of HHT, guidelines methodologists, health care workers, health care administrators, HHT clinic staff, medical trainees, patient advocacy representatives and patients with HHT. The Working Group determined clinically relevant questions during the pre-conference process. The literature search was conducted using the OVID MEDLINE database, from 1966 to October 2006. The Working Group subsequently convened at the Guidelines Conference to partake in a structured consensus process using the evidence tables generated from the systematic searches. The outcome of the conference was the generation of 33 recommendations for the diagnosis and management of HHT, with at least 80% agreement amongst the expert panel for 30 of the 33 recommendations.
Introduction

HHT is an autosomal dominant disease with an estimated prevalence of 1/5000[1] and is thought to be present in all races and parts of the world. Though epistaxis is the most common symptom of HHT and mucocutaneous telangiectasia the most common sign[2], HHT is also frequently complicated by the presence of arteriovenous malformations (AVMs) in the brain, lung, gastrointestinal (GI) tract and liver.

Unfortunately, HHT is often not diagnosed and entire families therefore remain unaware of available screening and treatment, and children and adults unnecessarily develop stroke or life-threatening hemorrhage. The goal of the international HHT guidelines process was to develop evidence-based consensus guidelines for the diagnosis of HHT, the prevention of HHT-related complications and treatment of symptomatic disease.

Methods

The overall guidelines process (Figure) was developed using the AGREE framework [3] with guidelines methodologists. The structure was that of a systematic evidence-based process with incorporation of expert evidence in a structured consensus process where evidence was lacking. We expected only weak or poor evidence in most areas, but chose this approach to maximize quality and applicability of the guidelines and provide a foundation for future research and guidelines in HHT.

Determination of Need for Guidelines

The need for clinical guidelines for HHT was identified by the HHT Foundation International, an international advocacy group for people with HHT, and the Foundation’s Scientific and Medical Advisory Board. This was based on their consistent observations of care gaps in HHT, specifically that HHT is under-diagnosed, that there are frequent delays in diagnosis and that most patients and families with HHT are not receiving appropriate preventative treatment. No clinical guidelines were in place for the multi-system manifestations of the disorder, with the exception of the recently published guidelines for liver vascular malformations (VMs)[4].

Membership of the HHT Guidelines Working Group

An organizing committee of clinicians, scientists, methodologists, patients and Foundation members selected the members of the HHT Guidelines Working Group. This included experts (clinical and genetic) from eleven countries, in all aspects of HHT, guidelines methodologists, health care workers and administrators, HHT Foundation representatives and patients with HHT. Each member was also a member of a topic subgroups [diagnosis, epistaxis, cerebral vascular malformations (CVMs), pulmonary AVMs (PAVMs), GI bleeding and liver VMs]. Patients contributed to the development of the clinically relevant questions and the recommendations, with particular input regarding values around recommendations.
Determination of Clinically Relevant Questions
During the pre-conference process, the topic subgroups worked by email to develop clinically relevant questions. The subgroups circulated and edited these through several iterations. These formed the basis for the literature review.

Background Preparation
A literature search was conducted using the OVID MEDLINE database from 1966 to October 2006 to identify relevant English-language publications, using the search strategies as outlined in Appendix I. Hand searches of relevant articles and reviews were also done for each clinically relevant question. Bibliographies of retrieved publications were reviewed to identify sources not obtained in our search. Publications in abstract form were included to minimize publication bias. One author (MEF) and the literature review assistant (J. Silver) independently reviewed abstracts and any relevant studies were pulled for review. Inclusion and exclusion criteria for study selection are listed in Appendix I. Results from selected studies were extracted into evidence tables, and along with original papers, were sent to participants for review, and to determine if any relevant literature was missing.

Determination of Clinical Recommendations
Participants convened at the Guidelines Conference to partake in a structured consensus process using the evidence tables. With the assistance of professional guidelines facilitators, topic subgroups prioritized clinically relevant questions and then generated recommendations for these. All participants assembled together afterwards to vote for all generated recommendations. Those recommendations achieving less than 80% agreement were further discussed, revised again with a facilitator, and re-voted. Wording of recommendations was considered final and are presented with the % agreement obtained on the final vote. Priorities for future research were also identified during the process (Appendix II).

Grading of evidence
Each recommendation was graded to indicate the level of evidence available using the classification system of the Canadian Task Force on the Periodic Health Examination [5] (Table 1). In addition, values around recommendations were generated using the GRADE instrument [6, 7] and these were reported as “strength of the recommendation”. The “strength of the recommendation” incorporated evidentiary and non-evidentiary factors, including baseline risks of outcomes, benefits of treatment, potential harms of treatment, certainty of point estimates, levels of evidence. Values were also incorporated, such as the importance of certain outcomes to stakeholders and other factors such as availability of certain tests, for example.

General Organization
The pre-conference process occurred by email over six months leading up to the two-day Guidelines Conference near Toronto, Canada, in November 2006. The Conference was held in a facility with anonymous key pad voting technology. The large group sessions were recorded (audio) and minuted.
Preparation of Report
Topic leaders generated each area of the manuscript, which was then revised by MEF, VP and the topic members for each group, and then reviewed by the other authors. The literature search referenced was that obtained in October 2006. At the time of final manuscript review, two steps were taken to assure that no generated recommendation needed immediate revision. First, a literature search for any interim Randomized Controlled Trials in HHT was performed, which revealed none. Secondly, the Working Group was polled for knowledge of any recent publications that would lead to a significant change in any of the recommendations and none were identified.

Role of Funding Sources
Although the funding organizations were not directly involved in the generation of the recommendations, some of the participants in the guidelines process were also board members of the HHT Foundation International and its Scientific and Medical Advisory Board. The other funding sources had no role in the design, conduct and reporting of the study or in the decision to submit the results for publication.

References
Abbreviations:

ACVRL1 = activin A receptor type II-like 1 gene
AgNO3 = silver nitrate
APC = argon plasma coagulation
AV = arteriovenous
AVF = arteriovenous fistula
AVMs = arteriovenous malformations
BIL = biliary
CAVM = cerebral arteriovenous malformations
CO2 = carbon dioxide
CT = computed tomography
CVMs = cerebral vascular malformations
DVA = developmental venous anomaly
EGD = esophagogastroduodenoscopy
ENG = endoglin
ENT = ear nose and throat
GI = gastrointestinal
HA = hepatic artery
HF = heart failure
HHT = hereditary hemorrhagic telangiectasia
HHT1 = hereditary hemorrhagic telangiectasia type 1
HHT2 = hereditary hemorrhagic telangiectasia type 2
IV = intravenous
MR = magnetic resonance
MRI = magnetic resonance imaging
PaO2 = arterial partial pressure of oxygen
PAVMs = pulmonary arteriovenous malformations
PHT = portal hypertension
PV = portovenous
TCD = transcranial Doppler
TTCE = transthoracic contrast echocardiography
VMs = vascular malformations
Diagnosis of HHT

Background

Making the diagnosis of HHT in a patient allows for the appropriate screening and preventative treatment to be undertaken in the patient and their affected family members. HHT has traditionally been diagnosed on the basis of its clinical features but can now also be diagnosed using genetic testing. We reviewed the evidence and expert experience for clinical and genetic diagnosis in HHT.

The clinical diagnostic features of HHT have been identified by describing the clinical presentation of individuals who have known or suspected HHT and their close relatives. The average age of onset for epistaxis is 12 years, with nearly 100% affected by age 40 years [1-4]. Most patients report the appearance of telangiectasias of the mouth, face or hands 5-30 years after the onset of nosebleeds; most commonly during the third decade. Unfortunately, there are no longitudinal natural history studies of HHT clinical manifestations and how these might vary with genotype.

In 2000, consensus clinical diagnostic criteria known as the Curaçao Criteria were published[5] (see Table 2). Using these criteria, a diagnosis of HHT is considered “definite” if 3 or more criteria are present, “possible or suspected” if 2 criteria are present, and “unlikely” if 0 or 1 criterion is present.

There have been no studies reporting sensitivity and specificity of the Curaçao Criteria, but the expert panel agreed that the Curaçao Criteria are particularly helpful in two situations: discriminating affected from non-affected older adults and ruling-in the diagnosis in younger adults and children. The expert panel was specifically concerned about the risk of missing diagnoses in children and young adults, who might have no epistaxis or visible telangiectases, yet have undiagnosed PAVMs or CVMs [6]. It is in these groups that genetic testing should be most useful.

The goal of genetic testing for HHT is to clarify the specific HHT mutation in an HHT family, allowing diagnosis among those relatives (often children and young adults) who do not meet clinical diagnostic criteria. Genetic testing is performed first on the index case in the family and involves DNA sequencing and deletion/duplication analysis of the coding exons of the endoglin gene (ENG, HHT1) and the activin A receptor type II-like 1 gene (ACVRL1, HHT2). Mutations in these genes account for the majority of cases of HHT. At least two other HHT loci have been described, though specific genes at these loci are not yet identified [7, 8]. Mutations in the SMAD4 gene can cause a rare syndrome which combines juvenile polyposis and HHT [9]. Genetic testing in HHT is complex relative to many other genetic conditions since a mutation in one of multiple genes can cause the condition, not all genes that can cause HHT have been discovered, and there are no “common mutations”, with most families having their own “private” HHT mutation.
Several authors have reported [10, 11] a clinical sensitivity/mutation detection rate of approximately 75% for sequence analysis of ENG and ACVRL1. Use of an additional method to detect large deletion/duplication mutations increases the detection rate by approximately 10%[10, 11]. Recent reports suggest that about 1-3% of patients clinically diagnosed with HHT will have a mutation detected in the SMAD4 gene, or about 10% of those who test negative for ENG and ACVRL1 mutations[11-13].

There is considerable clinical overlap between patients/families with ENG mutation and those with ACVRL1 mutation, with VMs reported in similar organs in both types [14-16]. The expert panel agreed that ENG versus ACVRL1 genotype should not significantly influence screening recommendations for VMs. Most HHT patients/families with SMAD4 mutation reported to date have juvenile polyposis and are therefore are at risk of GI malignancy [9, 12].

There is currently no evidence about impact of prenatal testing for HHT and no consensus among experts about how fetal diagnosis might alter pregnancy or delivery management. Expert experience is that prenatal diagnosis is not commonly sought in HHT, and is most often requested as an alternative to postnatal diagnostic testing when there is already another reason for performing prenatal testing.

**Recommendations**

| The expert panel recommends that clinicians diagnose HHT using the Curaçao Criteria (see Table) or by identification of a causative mutation. | Level of evidence: III  
Strength of recommendation: Weak  
Agreement: 82% |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Considerations:</strong> Applying the Curaçao Criteria for clinical diagnosis of HHT requires a targeted, multi-generation family history for HHT, given that most individuals with HHT will have an affected parent, grandparent and other close relatives. When applying the Curaçao Criteria, the clinician should consider the patient’s age, given the frequently delayed appearance of the signs and symptoms of HHT. At least 90% of patients with HHT meet the clinical criteria by age 40, but few do in the first decade of life. If a patient has clinical features suggestive of HHT, but no family history, it is possible that patient has a new mutation and therefore the diagnosis of HHT remains possible.</td>
<td></td>
</tr>
</tbody>
</table>
| The expert panel recommends that clinicians consider the diagnosis of HHT in patients with one or more Curaçao criteria (see Table). | Level of evidence: III  
Strength of recommendation: Weak  
Agreement: 91% |
| **Clinical Considerations:** When applying the Curaçao Criteria for clinical diagnosis, identifying 2 or less of the criteria after clinical examination and history should not be | |
considered sufficient evidence to rule out the diagnosis, particularly in the first few decades of life.

**The expert panel recommends that asymptomatic children of a parent with HHT be considered to have possible HHT, unless excluded by genetic testing.**

**Clinical Considerations:** Given the expected poor sensitivity of the Curaçao Criteria for clinical diagnosis in children, the clinician can clarify the diagnosis using genetic testing, if a familial mutation has been identified. If genetic testing is not possible, the clinician should proceed as if the child has HHT and consider appropriate screening for visceral AVMs.

| Clinical Considerations: Genetic testing for HHT is a multi-step process. In an experienced lab, the index case is generally tested by sequence and deletions/duplications analysis of both the ENG and ACVRL1 genes. It is reasonable to perform the deletion/duplication analysis either simultaneously with the sequence analysis or only in cases in which the sequence analysis is negative or equivocal. |
| If an HHT causing mutation is identified in the index case (test is positive), diagnostic genetic testing for HHT can be offered to all at risk relatives. These relatives would have “family specific” mutation testing by targeted sequencing. |
| If no mutation is identified (test is negative) in the index case, diagnostic genetic testing can not be offered to other family members. Such families should be advised that, in the future, currently undetectable HHT mutations will become detectable as new genes and testing methods are discovered. In the meantime, diagnosis and medical management of at risk family members will rely on clinical findings and knowledge of the natural history of HHT. |

| The expert panel recommends that clinicians refer patients for diagnostic genetic testing for HHT |
| 1. To identify the causative mutation in a family with clinically confirmed HHT |
| 2. To establish a diagnosis in relatives of a person with a known causative mutation, including: |
| a. Individuals who are asymptomatic or minimally symptomatic |
| b. Individuals who desire prenatal testing |
| 3. To assist in establishing a diagnosis of HHT in individuals who do not meet clinical diagnostic criteria |

**Clinical Considerations:** Genetic testing for HHT is a multi-step process. In an experienced lab, the index case is generally tested by sequence and deletions/duplications analysis of both the ENG and ACVRL1 genes. It is reasonable to perform the deletion/duplication analysis either simultaneously with the sequence analysis or only in cases in which the sequence analysis is negative or equivocal.

| Level of evidence: III |
| Strength of recommendation: Weak |
| Agreement: 87% |

| Level of evidence: III |
| Strength of recommendation: Weak |
| Agreement: 80% |
If a genetic variant of uncertain significance is identified (test is equivocal) in the index case, additional confirmatory testing may be available, or additional interpretive information may become available in the future, to clarify whether the genetic variant in question is in fact a benign variant or a disease causing mutation.

**The expert panel recommends that for individuals who test negative for ENG and ACVRL1 coding sequence mutations, SMAD4 testing should be considered to identify the causative mutation.**

**Clinical Considerations:** If full gene analysis for the ENG and ACVRL1 genes is negative, the next step is for the clinician to request similar testing of the SMAD4 gene.

**The expert panel recommends that all HHT patients and their families with SMAD4 gene mutations should undergo gastrointestinal screening for polyposis and gastrointestinal malignancies as per national screening recommendations.**

**Clinical Considerations:** Appropriate screening for patients and with the SMAD4 gene mutations includes colonic screening for polyposis with colonoscopy, starting at age 15-18 and every one to two years thereafter. The first colonoscopy should be performed at an age five years younger than that at which the youngest family member developed colon cancer. Affected patients should also undergo upper GI surveillance with esophagogastroduodenoscopy (EGD)/enteroscopy/small bowel series or capsule study starting at age 25 and every one to two years thereafter in accordance with previously published guidelines[17].

**References**


Epistaxis

Background:
Recurrent spontaneous epistaxis is the most common symptom of HHT and often leads to iron-deficiency anemia[1]. Epistaxis appears before the age of 20 years in about 50% of patients, with 78 – 96% of all HHT patients developing it eventually[2]. During the guidelines development process, patients identified epistaxis as a priority HHT-related health concern affecting their everyday life and the literature suggests that epistaxis is an important factor reducing quality of life in HHT[3]. We reviewed the evidence for treatment of HHT-related epistaxis, searching for studies regarding treatment of the usual chronic recurrent epistaxis as well as of acute episodes of epistaxis requiring urgent medical consultation.

Non-invasive management of chronic recurrent epistaxis in HHT has focused to date on prevention of epistaxis events through measures to maintain integrity of the nasal mucosa, such as humidification. The rationale for humidification is that endonasal crusting and airflow lead to damage of endonasal telangiectasia and secondary bleeding whereas humidification should help prevent endonasal crusting. There are small case series of various topical medications, including lubricants (saline, antibiotic ointments, etc.)[4, 5], as well as topical estrogen cream/ointment[6] and antifibrinolytics[7], with variable success in decreasing HHT-related epistaxis. There is insufficient published data to recommend one topical therapy over another, however expert experience is that there is mild benefit from humidification and that the risk of topical lubricants and saline is very low.

Procedural therapies for chronic HHT-related epistaxis include endonasal laser, electrical or chemical coagulation techniques, replacement of the fragile endonasal mucosa by skin or buccal mucosa (dermoplasty), nasal artery embolization and closure of the nasal cavity (known as Young’s procedure). There have been no controlled or well designed comparative studies of any of these procedures in HHT-related epistaxis, for either acute or chronic management. Case series and expert opinion of endonasal coagulation for treatment of moderate HHT-related epistaxis suggests that most types of endonasal coagulation appear to be low-risk procedures with subjective improvement in most patients[1, 4, 8-12]. Chemical cautery (e.g. AgNO3) and CO2-laser-coagulation appear to have poorer outcomes in HHT and higher risk of intraoperative bleeding[4]. Septal dermoplasty has been reported, in one uncontrolled retrospective case series of patients with severe epistaxis, to decrease mean transfusion requirements and to improve subjective quality of life, but follow-up was available in <50% of treated patients[13] and complications included endonasal crusting and dryness. Young’s procedure has been shown in a few small case series of patients with severe epistaxis to cause cessation of epistaxis and also to improve in quality of life, though patients report side effects of chronic mouthbreathing[14-16]. Nasal artery embolization is generally not useful for treatment of chronic epistaxis, since the effect is generally short-term[17, 18]. Submucosal or intravascular endonasal injections of different substances have been reported[19, 20], often with reduction in epistaxis but also reports of complications such as severe allergic reactions and blindness[20].
The expert panel agreed that given the learning curve for surgical management of chronic HHT-related epistaxis, involvement of surgeons with expertise in HHT-related epistaxis may increase the likelihood of appropriate choice of treatment and improve outcomes of therapy. The expert panel also agreed that this applied to nasal surgery for indications other than epistaxis, in HHT patients.

Several medical therapies have been reported for HHT-related epistaxis, but there are no well designed studies supporting their effectiveness and most studies have been limited by the lack of a validated sensitive outcome measure. There is one negative randomized placebo-controlled double-blind trial of estrogen [21], and another of tranexamic acid [22], in which investigators were unable to demonstrate significant improvement in hemoglobin (primary outcome) but did demonstrate significant improvement in subjective epistaxis (secondary outcome)[22].

There are no well designed studies of the first-line management of acute epistaxis, though nasal packing is frequently used to control acute bleeding. However, endonasal telangiectasia are extremely fragile and therefore packing removal can cause re-bleeding. This can be minimized with atraumatic packing, for example using lubricated or pneumatic packing, the latter allowing insertion and removal of the packing in a deflated size. Low pressure pneumatic packing may also minimize mucosal ischemic damage. Two uncontrolled case series of embolization[18, 23], in patients with severe ongoing epistaxis despite packing, reported excellent immediate success rates (80-100%), but with early recurrence of epistaxis and risk of serious procedural complications (stroke, tissue necrosis).

The panel also discussed management when an HHT patient has an indication for antiplatelet or anticoagulant therapy. There are no published studies regarding the use of anticoagulants in HHT, but expert experience revealed a wide range of outcomes, with some HHT patients tolerating anticoagulation and others developing life-threatening bleeding.

**Recommendations**

| The expert panel recommends that physicians advise patients with HHT-related epistaxis to use agents that humidify the nasal mucosa to prevent epistaxis. | Level of evidence: III
Strength of recommendation: Weak
Agreement: 94% |
|---|---|
| The expert panel recommends that for HHT-related epistaxis requiring surgical intervention, clinicians consider endonasal coagulation as a first line treatment option. | Level of evidence: III
Strength of recommendation: Weak
Agreement: 93% |

**Clinical Considerations:** Endonasal coagulation should be
applied carefully and with experience to avoid complications like septal perforation (which often leads to worse epistaxis), even if it means repeating the intervention several times. If recurrent endonasal coagulation has not been effective and epistaxis is severe, then more invasive procedures, such as septal dermoplasty or Young’s procedure, can be considered.

| The expert panel recommends that clinicians refer HHT patients with epistaxis and who desire treatment to otolaryngologists with HHT expertise for evaluation and treatment. | Level of evidence: III
Strength of recommendation: Weak
Agreement: 87% |
| --- | --- |

Clinical considerations: Primary physicians are key players in the care of HHT patients, especially in the emergency situation. In the patient with epistaxis problematic enough to warrant consideration of treatment, consultation with an otolaryngologist with HHT expertise should help guide the intervention choice, to maximize effectiveness and reduce risk, in this life-long rare disorder.

| The expert panel recommends that when considering nasal surgery for reasons other than epistaxis, the patient and clinician obtain consultation from an otolaryngologist with expertise in HHT-related epistaxis. | Level of evidence: III
Strength of recommendation: Weak
Agreement: 100% |
| --- | --- |

Clinical Considerations: In the patient with HHT and an unrelated ENT problem requiring surgery, consultation with an otolaryngologist with HHT expertise should help guide the procedural interventions to minimize risk of worsening epistaxis.

| The expert panel recommends that the treatment for acute epistaxis requiring intervention include packing with material or products that have a low likelihood of causing re-bleeding with removal (e.g., lubricated low-pressure pneumatic packing). | Level of evidence: III
Strength of recommendation: Weak
Agreement: 93% |
| --- | --- |

Clinical considerations: In order to perform atraumatic packing, the clinician can lubricate the packing or use a pneumatic packing which allows insertion and removal of the packing in a deflated size. When using pneumatic packing, a low pressure packing would be preferable. This recommendation is specifically addressing nasal packing performed by physicians, though the expert panel is aware that patients often choose to self-pack the nose.

| The expert panel recommends that HHT-related epistaxis is not an absolute contraindication to anticoagulant/antiplatelet therapy. | Level of evidence: III
Strength of |
| --- | --- |
Anticoagulant/antiplatelet therapy can increase the risk of epistaxis and the decision to use these agents should be based on the individual patient risk and benefits.

Clinical Considerations: HHT-related epistaxis will seldom, if ever, lead to sudden death while the use of anticoagulants/antiplatelets may prevent catastrophic or life-threatening events. In most HHT patients in whom visceral sources for life-threatening hemorrhage (i.e., significant PAVMs and CVMs) have been ruled out, a trial of anticoagulation can be considered if indicated. Referral to an otorhinolaryngologist with expertise in HHT should be considered, prior to starting anticoagulation therapy, to create a prior treatment plan in the event of a catastrophic bleeding event and to consider preventive surgical procedures.

recommendation: Strong Agreement: 100%

References


Cerebral Vascular Malformations

Definition
The term cerebral vascular malformation (CVM) refers to a variety of vascular abnormalities, classified based on morphology, including: (1) arteriovenous malformations (CAVM) (including microAVMs measuring less than 1 cm in size); (2) cavernous malformations; (3) venous angiomas/developmental venous anomalies (DVA); (4) capillary telangiectasia, enlarged capillary-sized vessels; (5) vein of Galen malformations; (6) high flow pial fistulae (AVF); and (7) mixed malformations [1]. All of these types of CVMs can be found in HHT patients, though typically HHT is associated with CAVMs, AVFs, microAVMs and telangiectasia [2].

Background
Approximately 23% of HHT patients will harbour a CVM [3-5]. The rationale for screening for CVMs in HHT, is that screening will detect a treatable CVM prior to the development of a life-threatening or debilitating complication. We therefore reviewed the evidence regarding complications of CVMs, the performance of screening tests and the effectiveness of treatment for CVMs. Given the rarity of HHT-related CVMs, most of the evidence reviewed relates to the more common sporadic CVMs.

The bleeding risk of CVMs in HHT has been estimated retrospectively at approximately 0.5% per year [6], though there are no prospective natural history studies. In larger series of sporadic CAVMs [7], the annual rate of rupture is 2-4%/year [7]. Based on case series, CAVMs and AVF appear to have a more aggressive natural history, while CM, capillary telangiectasia and DVA, also reported to occur in HHT [4], appear to have a more benign natural history [3, 6, 8-10]. There are several case series and reports of catastrophic hemorrhagic sequelae of CVMs and spinal AVFs occurring during childhood [5, 11-14]. Rarely, spontaneous resolution of CVMs has been reported [15, 16].

The typical imaging features of HHT CVMs include the presence of either multiple, cortical, micro AVMs or AVFs harboring single feeding arteries and single draining veins [8-10]. Catheter angiography remains the gold standard for diagnosis of most types of CVMs, but carries a 0.5% risk of permanent stroke [17]. Magnetic resonance imaging (MRI) is considered to be a safe, non-invasive modality to screen for CVMs, but unfortunately there are no screening studies assessing its performance in HHT. MRI screening studies for non-HHT CVMs have been limited by small size, retrospective design and lack of blinding to clinical status, but suggest sensitivity of 80-95% for medium to large sized CVMs [18-20]. MRI is less sensitive for the detection of micro AVMs [20] but the addition of contrast enhancement (gadolinium for patients > 2 years of age) to MRI sequences increases the sensitivity for microAVMs. The inclusion of sequences designed to detect blood products (currently gradient echo sequences) also increases the sensitivity of MRI for microAVMs and signs of asymptomatic hemorrhage [11]. “False-positive” results may occur when other types of CVMs are encountered including telangiectasias which have a favorable natural history [4] and for which no further invasive imaging is required. Transcranial doppler (TCD) ultrasonography has also been used to screen for CVMs, [21, 22] with reported sensitivity of approximately
80% for medium to large-sized CVMs, but studies are limited by sample size and design. No evidence exists for follow-up screening after an initial negative study, as there is no evidence to suggest that adult patients with HHT develop new CVMs.

MRI provides a relatively safe, sensitive testing modality to identify CVMs in children[23]. While MRI itself poses little risk, the expert panel acknowledges the risk related to sedation/anaesthesia of children for diagnostic procedures. Of greatest concern is the risk of respiratory depression, but this should be minimized with appropriate cardiorespiratory monitoring. No evidence exists at this time to recommend follow-up screening after an initial negative study during childhood, but consideration should be given to one adulthood MRI following initial negative childhood MRI.

The expert panel agreed CVM obliteration is required to effectively eliminate the future risk of hemorrhage. Although treatment may provide a large relative risk reduction for cerebral bleeding, procedural risks are significant. There are no published studies of the efficacy or safety of any form of treatment of CVMs in HHT patients. However, several large case series (>200 patients, mostly single-center) of embolization, microsurgery and stereotactic radiation in non-HHT CAVMs, show widely ranging effectiveness for each modality[4, 9, 12, 24-34]. Based on this, as well as expert experience, the expert panel agreed that effective treatment strategies include embolization, microsurgery and stereotactic radiation, or combinations of these. With the rarity of CVMs and the associated risks of treatment, the expert panel agreed that each case should be managed in an individualized manner and that decisions about invasive testing and therapy should occur at centers with significant experience and expertise in all treatment modalities. Though there is no evidence regarding differences in outcomes according to expertise in management of these cases, the expert panel agreed that centers with experience in HHT-related CVMs will be more aware of important issues related to the care of HHT patients and likely to have better outcomes of surgical and other procedures.

CVMs occur in infants and children with HHT[2, 5, 10, 13, 35, 36]. Before the age of 6 these malformations tend to be high flow pial fistulae (cerebral or spinal cord AVF)[2]. Expert opinion is that these malformations have a more aggressive natural history than nidus type CAVMs, including presenting events such as intracerebral hemorrhage, cognitive deficit, cardiac insufficiency, epilepsy and hydrocephalus[2, 10, 35, 36]. Embolization or microsurgical obliteration of these high flow pial fistulae in children may therefore be of significant benefit when performed by a neurovascular center with expertise in these techniques in children.

There is no evidence to guide the management of CVMs during pregnancy and delivery, as there is no good evidence regarding the risk of CVM complications or treatment during pregnancy and delivery.

**Recommendations**

<table>
<thead>
<tr>
<th>The expert panel recommends that the clinician screen adult patients with possible or definite HHT for cerebral vascular malformations.</th>
<th>Level of evidence: III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strength of</td>
<td></td>
</tr>
</tbody>
</table>
**Clinical Considerations:** Dissension resulted primarily from the lack of evidence of treatment effectiveness for asymptomatic CVMs in HHT and therefore the lack of evidence for benefit of screening.

The specifics regarding screening method are detailed in the next recommendation. There is no evidence for any role for repeat MRI screening in adults, after an initial negative study. The likelihood of detecting a CVM will be less in patients with only a “possible” diagnosis of HHT, but that screening in these patients may be reasonable if the diagnosis of HHT cannot be ruled out genetically.

The expert panel could not generate a recommendation regarding screening for spinal AVFs, given their rarity and absence of evidence. However, if screening for spinal AVFs is being considered in children with HHT, a sagittal T2 MRI of the spine would be appropriate.

The expert panel recommends the use of MRI for cerebral vascular malformation screening in adults with possible or definite HHT using a protocol with and without contrast administration and using sequences that detect blood products, to maximize sensitivity.

**Clinical Considerations:** If patients have received previous embolization, coil compatibility with MRI must be confirmed prior to MR examination. The expert panel acknowledges that the optimum age for adult screening remains unknown but felt that age 18 was appropriate as patients enter adulthood. In the presence of a negative MRI in adulthood no further screening tests are suggested. There may be additional benefits to performing an MRI at initial assessment, in the detection of infarcts and other CNS complications of HHT.

The expert panel recommends that the clinician screen children with possible or definite HHT for cerebral vascular malformations in the first 6 months of life (or at time of diagnosis) with an unenhanced MRI, and refer all patients with an MRI positive for these lesions to a center with neurovascular expertise for consideration of invasive testing and further management.

**Clinical Considerations:** Dissension resulted primarily from the lack of evidence of treatment effectiveness for asymptomatic CVMs in HHT and therefore the lack of evidence for benefit of screening, as well as greater risk of
screening in children.

When MR screening is performed with the use of sedation and anesthesia in young children, it is necessary to monitor cardiorespiratory parameters during the procedure and to provide an equivalent standard of care as that provided in an operating room. The technique utilized to sedate/anesthetize infants for MRI should be performed in accordance with local expertise and no undue risk be taken to obtain such a screening test. The MRI would generally be planned at the time of HHT diagnosis, preferably before 6 months of age when the risk benefit ratio would be optimal.

**The expert panel recommends that adults presenting with an acute hemorrhage secondary to a cerebral vascular malformation be considered for definitive treatment in a center with neurovascular expertise.**

- Level of evidence: III
- Strength of recommendation: Strong
- Agreement: 94%

**The expert panel recommends that all other adults with cerebral vascular malformations be referred to a center with neurovascular expertise to be considered for invasive testing and individualized management.**

- Level of evidence: III
- Strength of recommendation: Strong
- Agreement: 84%

**Clinical Considerations:** The expert panel recognizes that asymptomatic CVMs discovered during screening of HHT patients may carry a more favorable natural history. These patients should be managed on an individualized basis. Since some CVMs may carry a favorable natural history, referral to a center with neurovascular expertise prior to performing invasive imaging (catheter angiography) may minimize unnecessary testing.

**The expert panel recommends that pregnant women with suspected or confirmed HHT harboring an asymptomatic CAVM during pregnancy have definitive treatment of their CAVM deferred until after delivery of their fetus. The expert panel recommends that the delivery of the fetus follow obstetrical principles.**

- Level of evidence: III
- Strength of Recommendation: Weak
- Agreement: 80%

**References**


Pulmonary Arteriovenous Malformations

Background

PAVMs are present in approximately 15-50% of people with HHT and have been associated with life-threatening complications, as previously reviewed [1, 2]. The rationale for screening HHT patients for PAVMs is that screening will detect a treatable PAVM prior to the development of a life-threatening or debilitating complication. We therefore reviewed the evidence regarding complications of PAVMs, the performance of screening tests and the effectiveness of treatment for PAVMs.

PAVMs have been shown to be associated with disabling and life-threatening complications, such as stroke, TIA, cerebral abscess, massive hemoptysis and spontaneous hemothorax [1, 3-6] in retrospective series. The neurologic complications are presumed to occur via paradoxical embolization through PAVMs whereas the hemorrhagic complications occur due to spontaneous PAVM rupture. These complications have been demonstrated in largely adult series of HHT patients, though they have also been demonstrated in a pediatric HHT series[7], albeit smaller in size. There have also been small series reporting these same complications during pregnancy [8, 9] and the expert panel agreed that the complication risk appears to be greater during pregnancy.

Since clinical symptoms and signs of PAVMs are frequently absent prior to the development of complications, a number of screening tests have been studied, including physiologic methods of measurement of intrapulmonary shunt as well as multiple imaging modalities. In the one comparative study (Table 3), transthoracic contrast echocardiography with agitated saline (TTCE) has been demonstrated to have the best combination of high sensitivity [2] and low-risk[10, 11] amongst screening tests for PAVMs in adults with HHT, when compared to the reference standard tests (CT and pulmonary angiography). There have been no comparative screening studies for PAVMs in children with HHT.

Embolization has been shown in several non-controlled series [3, 5, 12-16] to be efficacious and to have a good safety profile, with only rare PAVM-related complications during 5-10 year follow-up (Table 4). In the short-term, these studies demonstrated very high rates of immediate technical success and significant improvement in oxygenation (Table 4). Longer term post-embolization, reperfusion did occur in up to 15% and growth of small PAVMs in up to 18% (Table 4) but clinical complications were very rare. These series primarily reported outcomes for treatment of PAVMs with feeding artery diameter of 3 mm or greater, though expert experience suggests that embolization of smaller PAVMs (2-3mm) has similar outcomes. The safety and efficacy were similar for large PAVMs in adults[17] as well as for PAVMs in children[7], though there is little experience with embolization of PAVMs in children under the age of 4 years. There is only one small case series of embolization during pregnancy[18], suggesting reasonable safety. Though there is no evidence regarding differences in outcomes according to expertise in embolization of PAVMs, the expert panel agreed that
centers with experience in this procedure are more likely to have better outcomes than inexperienced centers.

The long-term follow-up of PAVMs is described using CT of the thorax. This allows detection of reperfusion by non-involution of aneurismal sac at approximately 1 year post-embolization and also detection of growth of small residual PAVMs, which are frequent in HHT[5]. TTCE has been shown to not be useful post-embolization, given that it remains positive in approximately 90% of patients post-embolization[19].

Recommendations

The expert panel recommends that clinicians screen all patients with possible or confirmed HHT for PAVMs.

Clinical considerations: Screening should be performed at the time of initial clinical evaluation for HHT. Although less evidence exists in children, the expert panel included children in the screening recommendation, since they are also at risk of life-threatening complications and treatment appears to be similarly effective.

In patients with negative initial screening, repeat screening should be considered after puberty, after pregnancy, within 5 years preceding planned pregnancy and otherwise every 5-10 years.

The expert panel recommends that clinicians use transthoracic contrast echocardiography as the initial screening test for PAVMs.

Clinical Considerations: Screening should be performed by clinicians with significant expertise in HHT, usually in an HHT center of excellence, to achieve the accuracy and low-risks reported in the literature. TTCE is considered positive if there is detection of any bubbles in the left atrium. Positive screening should be confirmed with unenhanced multidetector thoracic CT with thin-cut (eg. 1-2mm) reconstructions. CT was not recommended as a screening test, due to the associated radiation exposure, but could be considered for screening in centers without expertise in TTCE for PAVM screening.

In children, the choice of screening tests should be decided on a case by case basis, but may include clinical evaluation (for cyanosis, dyspnea, clubbing), supine and upright pulse oximetry, chest radiography and/or TTCE.
**The expert panel recommends that clinicians treat PAVMs with transcatheter embolotherapy.**

**Clinical Considerations:** The recommendation applies to all adults with PAVMs and children with symptomatic PAVMs. The decision to treat in *asymptomatic children* (no dyspnea, no exercise intolerance, no growth delay, no cyanosis or clubbing, no previous complication) should be made on a case by case basis. The selection of PAVMs for embolization is based on feeding artery diameter, generally 3mm or greater, though targeting PAVMs with feeding artery diameter as low as 2 mm may be appropriate.

This procedure should be performed by clinicians with significant expertise in embolizing PAVMs, usually in an HHT center of excellence, to achieve the effectiveness and low-risks reported in the literature. This is particularly relevant when considering embolization in rare or higher risk situations, such as during pregnancy and in patients with mild-moderate pulmonary hypertension. The panel agrees there is no role for surgical management of PAVMs, other than in the management of life-threatening bleeding in a center where embolization expertise is unavailable.

<table>
<thead>
<tr>
<th>The expert panel recommends that clinicians provide the following long-term advice to patients with documented pulmonary AVMs (treated or untreated):</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Antibiotic prophylaxis for procedures with risk of bacteremia</td>
</tr>
<tr>
<td>2. When IV access is in place, take extra care to avoid IV air</td>
</tr>
<tr>
<td>3. Avoidance of SCUBA diving</td>
</tr>
</tbody>
</table>

**Clinical Considerations:** The rationale for recommending prophylactic antibiotics for bacteremic procedures in people with PAVMs, is based on expert opinion that cerebral abscess is frequent in these patients (approximately 10% before PAVM diagnosis), that cerebral abscess in these patients occurs primarily as a complication of bacteremic procedures, the fact that cerebral abscess is associated with considerable morbidity and mortality and that this precaution is low-risk. The AHA guidelines for prevention of bacterial endocarditis should be followed for choice of antibiotics.

Similarly, careful avoidance of intravenous air bubbles is recommended to prevent cerebral air embolism, and this could include an in-line filter. There are only theoretical arguments

| Level of evidence: II |
| Strength of recommendation: Strong |
| Agreement: 96% |

| Level of evidence: III |
| Strength of recommendation: Weak |
| Agreement: 87% |
for avoidance of SCUBA suggesting that there may be an increased risk of complications of decompression in patients with PAVMs.

These precautions should be followed life-long, regardless of size of PAVMs, even once PAVMs are treated. These precautions should also be considered in HHT patients in whom PAVMs have not been excluded or in whom microscopic PAVMs are suspected (for example, detected on TTCE but not detectable on CT).

The expert panel recommends that clinicians provide long-term follow-up for patients who have PAVMs, in order to detect growth of untreated PAVMs and also reperfusion of treated AVMs.

Clinical Considerations: Follow-up allows the identification of embolized PAVMs that have reperfused and other PAVMs that have grown large enough to be considered for embolization. Multidetector thoracic CT with thin-section reconstruction (1-2mm) should be undertaken within 6-12 months after embolization and then approximately every 3 years after embolization.

For patients with only small untreated PAVMs and in patients with suspected microscopic PAVMs (for example, detected on TTCE but not detectable on CT), the follow-up period should be determined on a case by case basis (approximately every 1-5 years) with CT (as above), with consideration for limiting radiation exposure.

Level of evidence: II
Strength of recommendation: Strong
Agreement: 100%

References

Gastrointestinal Bleeding

Background
Although 80% of patients with HHT have gastric or small intestinal telangiectasia [1] on endoscopy or capsule examination, only 25-30% of patients will develop symptomatic GI bleeding [2-5] which usually does not present until the fifth or sixth decades of life. Patients rarely develop significant GI bleeding before 40 years of age [2-5]. Women are affected with GI bleeding in a ratio of 2-3:1 [6, 7].

Patients with HHT and GI bleeding may or may not be symptomatic, as the bleeding is usually in a slow, chronic and intermittent fashion, often without notable melena. Patients often have few symptoms until they become anemic. In severe cases, HHT GI bleeding causes morbidity, dependency on blood transfusions and increased mortality[6]. Severity of GI bleeding in HHT is generally based on severity of the anemia. Gastric and duodenal telangiectasia are more common than colonic telangiectasia and contribute more to overall GI bleeding and chronic anemia in HHT patients[8].

Presently, endoscopic evaluation is considered the gold standard test for evaluation of GI bleeding in HHT patients. Though the majority of patients with HHT will have GI telangiectasia, the utility of endoscopic evaluation is in the anemic or iron-deficient patient. The presence and number of gastric and duodenal telangiectasia have been shown to predict the presence and number of jejunal telangiectasia [7] and therefore, for diagnostic purposes, an esophagogastroduodenoscopy (EGD) is sufficient in most cases.

Management of GI bleeding in HHT involves treatment of the iron-deficiency/anemia and therapies to reduce GI bleeding. Treatment of anemia and iron deficiency includes aggressive iron replacement and blood transfusions as necessary. There are no studies of iron replacement in HHT, but experts agree that oral iron supplementation may be sufficient in some patients, though consideration of intravenous iron supplementation may be necessary in more severe cases. There have been no studies of erythropoietin therapy in HHT, but it is sometimes considered in severe cases, in combination with iron, in an attempt to accelerate treatment of the anemia.

Current treatment options to reduce chronic GI bleeding in HHT include hormonal therapy (estrogen-progesterone preparations or danacrine), anti-fibrinolytics (aminocaproic acid or tranexamic acid), other medications reported only as isolated case reports (tamoxifen, interferon, thalidomide and sirolimus) and endoscopic therapy. There is one small double-blind placebo-controlled crossover trial[9] (Table 5) of combination hormonal therapy (ethinylestradiol 0.050 mg plus norethisterone 1 mg) versus placebo, each for six months, in 10 patients with transfusion dependent severe GI bleeding. Five of the six HHT patients had no further GI bleeding while on treatment and, in the overall group, there was a significant decline in transfusion requirements. In a retrospective case series[6] of 43 HHT patients with GI bleeding, median haemoglobin improved significantly (8.6 to 9.8, p=0.0018) for the 23 patients treated with medical therapy (ethinyl estradiol/norethindrone in 19, danacrine in 2 and aminocaproic acid in 2). Though there are only other individual case reports[10] of danacrine in HHT GI bleeding,
it may be a reasonable alternative to estrogen/progesterone therapy in male patients, as it
does not have feminizing effects. There is only individual case report evidence for
antifibrinolytics for HHT-related GI bleeding [11], but there is expert experience
suggesting benefit in these patients. Overall, there is insufficient evidence to
recommend any medical therapy as first line therapy in these patients, given the potential
side effects, however there may be a role for these agents when iron replacement is
insufficient to control anemia.

There are small case series (Table 5) and expert experience suggesting that local
endoscopic therapy, using argon plasma coagulation (APC) or ND-YAG laser, may be
beneficial in reduction of HHT-related GI bleeding. In three small case series [12-14] of
repeated ND-YAG therapy, transfusion requirements declined in more than 50% of
patients. The expert panel agreed that though the reported series were primarily of the
use of ND-YAG laser, that APC is the most effective method of endoscopic therapy
currently available. Overall, there is insufficient evidence to recommend endoscopic
therapy as first line therapy in HHT-related GI bleeding; however there may be a role for
endoscopic therapy when iron replacement is insufficient to control anemia. There is no
evidence or experience supporting cauterization of colonic telangiectasia, or for surgery
or transcatheter embolotherapy in the routine management of HHT-related GI bleeding.
Though there is no evidence regarding differences in outcomes according to expertise in
endoscopic management of GI bleeding in HHT, the expert panel agreed that clinicians
with experience in HHT-related GI bleeding will better prepared to make decisions about
when to treat GI telangiectasia in HHT and are likely to have better outcomes of these
procedures.

There is no evidence of any benefit in altering nutrition or life style, or for screening for
Helicobacter pylori in patients with HHT-related GI bleeding. HHT patients with GI
bleeding should avoid anticoagulants and medications that alter platelet function.
However, when other comorbidities require use of these medications, expert experience
is that these can often be tolerated, especially when doses are kept as low as possible.

**Recommendations**

| The expert panel recommends that all patients over 35 years should have annual hemoglobin or hematocrit levels measured because of the increased risk of significant gastrointestinal bleeding with age. Directed endoscopic evaluation should be undertaken in patients with anemia disproportionate to epistaxis. The expert panel advises against gastrointestinal endoscopic investigations in patients with HHT and no evidence of anemia. | Level of evidence: III |
| Clinical Considerations: A blood test for haemoglobin and ferritin should be drawn as part of the annual physical examination with the family physician. The age of 35 is preferred as few people begin having problems with GI | Strength of recommendation: Strong |
| | Agreement: 89% |
bleeding before 40 and this allows measurement of baseline hemoglobin to track GI losses. Patients over 50 years of age, particularly women, are considered at higher risk of HHT-related GI bleeding. Of note, fecal occult blood testing can be falsely positive due to GI transit of swallowed epistaxis and therefore this test is not useful.

| In HHT patients with suspected gastrointestinal bleeding, the expert panel recommends that an upper endoscopy be the first diagnostic test. The diagnosis of HHT-related gastrointestinal bleeding is made in the presence of anemia and endoscopic visualization of characteristic gastrointestinal telangiectasia in combination with clinical judgment. |
| Level of evidence: III |
| Strength of recommendation: Strong |
| Agreement: 90% |

**Clinical Considerations:** HHT patients with anemia should be referred to clinicians with HHT expertise for endoscopic visualization to identify the source of their GI bleeding. Since the majority of the bleeding occurs in the stomach and proximal small intestine, an upper endoscopy is usually sufficient to diagnose upper GI telangiectasia. The clinician must be aware that the presence of characteristic GI telangiectasia does not necessarily indicate that they are the source of anemia or GI bleeding and does not preclude other sources of bleeding. Wireless capsule endoscopy may be considered when direct endoscopic visualization of the GI tract with upper and lower endoscopies does not adequately explain the anemia.

It is uncommon for the GI telangiectasia in HHT to cause massive, acute GI bleeding. In HHT patients with acute GI bleeding, therefore, other causes should be considered first as in non-HHT patients.

**The expert panel recommends oral and/or IV iron supplementation as first line therapy for mild anemia and chronic bleeding secondary to HHT-related telangiectasia.**

**Clinical Considerations:** For replenishment of iron stores the clinician can select the oral iron formulation that is best tolerated by the patient, as long as the dosing is adequate. Often patients will require 6-12 months of, for example, ferrous fumarate 300mg OD, but the dose and duration are adjusted according to the patient’s haemoglobin and ferritin response. If one oral iron preparation is not tolerated, then a trial of another should be considered. If oral iron replacement is insufficient or not tolerated, then intravenous iron, preferably iron sucrose, should next be considered.

| Level of evidence: III |
| Strength of recommendation: Weak |
| Agreement: 97% |
Hemoglobin and ferritin levels should be monitored regularly, with the frequency depending on the severity of the anemia, until both the anemia and iron deficiency are resolved. Some patients may require long-term or life-long iron supplementation. If additional therapy with erythropoietin is considered, patients should be screened and treated for PAVMs before initiating therapy, due to the thrombogenic risk of erythropoietin.

**Clinical Considerations:**
The HHT patient with anemia not responding to iron supplementation should be referred to a clinician with expertise in endoscopic treatment of HHT patients, for consideration of one or two attempts to locally cauterize visible telangiectasia. This is most likely to be beneficial when performed with APC and by endoscopist with related experience. Since the majority of the bleeding occurs in the stomach and proximal small intestine, cauterization during upper endoscopy is most likely to be beneficial. If initial endoscopic cauterization is not beneficial in a given patient, further multiple attempts at endoscopic cauterization of GI telangiectasia are unlikely to be beneficial and yet will expose the patient to unwarranted risk. Specialized endoscopy, such as enteroscopy, or performing endoscopy during surgery, are not routinely used for treatment of HHT-related bleeding, but may be considered in cases where treatment of more distal lesions is being considered (distal to the duodenum and proximal to the terminal ileum).

| The expert panel recommends against the use of multiple attempts at local endoscopic therapy because of the additive risk of adverse events without corresponding benefits. |
| Level of evidence: III |
| Strength of recommendation: Weak |
| Agreement: 90% |

| The expert panel recommends that the clinician consider systemic hormonal or antifibrinolytic therapy in selected HHT patients to limit ongoing gastrointestinal blood loss. |
| Level of evidence: III |
| Strength of recommendation: Weak |
| Agreement: 100% |

**Clinical Considerations:** When unable to maintain the hemoglobin at an acceptable level, i.e., 9-10 gm/dl or higher, with oral and/or intravenous iron, then the clinician should consider hormonal therapy or antifibrinolytic therapy, in patients without contraindications. The usual dosing for hormonal therapy in HHT, based on the one study [9], is daily ethinylestradiol 0.050 mg and norethisterone 1 mg. Danacrine 200 mg orally TID for six weeks followed by 200 mg daily in responders may be a beneficial alternative in men, with less side effects. Another alternative is antifibrinolytic
therapy, with aminocaproic acid or tranexamic acid. Aminocaproic acid is usually started at 500 mg orally QID and increased to a maximum of 2500 mg orally QID (10 gms/day). Tranexamic acid is usually started at 500 mg orally every 8-12 hours and increased to 1-1.5 grams orally every 8-12 hours. Patients should be screened and treated for PAVMs before initiating either of these systemic therapies, given the thrombogenic risk.

References
Liver Vascular Malformations

Background:
Though a consensus guideline had been recently published for the diagnosis and management of liver VMs in HHT[1], to be consistent, we elected to include this topic in the present guidelines. As such, we followed the same guidelines process for liver VMs as for other aspects of HHT and reviewed the evidence regarding diagnosis and treatment of liver VMs in HHT. The Liver VMs recommendations reported in the present guidelines do not differ significantly from the previous guidelines for liver VMs[1].

Liver VMs are present in 32-78% of HHT patients [2-6] (Table 6). Though there is no published natural history data regarding liver VMs in HHT, it appears that symptoms occur in only about 8% of the patients with HHT and liver VMs [4, 7]. The clinical presentations of liver VMs include high-output heart failure, portal hypertension and biliary necrosis, as detailed in a recent review[8].

In patients who have symptoms suggestive of liver VMs[8], it is important to establish the diagnosis of liver VMs for therapeutic and prognostic purposes. The diagnosis of liver VMs may also assist in the clinical diagnosis of HHT, since visceral involvement is one of the clinical diagnostic criteria [9]. Several different imaging modalities have been reported and studied for the screening and diagnosis of liver VMs in HHT. From the least invasive to the most invasive, these tests are Doppler ultrasonography (US), magnetic resonance imaging (MRI), triphasic spiral computed tomography (CT) and mesenteric angiography. Doppler US is the least invasive test, requiring no contrast and being associated with no procedural complications. There is little experience with MRI, which does require MR-contrast administration but involves no radiation exposure. CT is associated with radiation exposure and risk of contrast allergy. Mesenteric catheter angiography has traditionally been considered the diagnostic “gold standard” but is the most invasive, and is rarely used.

Typical angiographic findings have been described in several small case series of HHT patients [10-12], including telangiectasia, confluent VMs, hepatic artery dilatation and shunting (arterioportal, arteriovenous and/or portovenous). Triphasic CT findings have been similarly described [2, 3, 7]. Several case series of Doppler US in HHT patients have demonstrated hepatic artery dilatation, elevated hepatic artery flow and intrahepatic hypervascularity [3, 4, 6, 13, 14]. There have been no well-designed studies reporting sensitivity and specificity of any of these tests, though the positive predictive value of Doppler US appears to be near 100% [5, 14]. Screening studies of HHT patients (Table 6) have reported a prevalence of liver VMs of 32%-72% with Doppler US[4-6] and 67-78% with triphasic CT[2, 3]. In none of these studies was a diagnostic gold standard (angiography) uniformly performed, however, these prevalences are all much higher than the symptomatic rate (8%), suggesting that these tests are sensitive. There are no screening studies in children.

Histological diagnosis from liver biopsy tissue, although quite characteristic [8], is unnecessary, given typical imaging findings, and risky in patients with liver VMs. Focal
nodular hyperplasia (FNH) occurs more frequently in HHT than in the general population[15] but can be diagnosed through imaging, without biopsy.

There are three uncontrolled case series (Table 7) of treatments of liver VMs, specifically hepatic artery embolization and liver transplantation. Hepatic artery embolization has the objective of reducing arteriovenous or arterioportal shunting by embolizing branches of the hepatic artery. Embolization appears to be effective in improving symptoms related to high output heart failure and mesenteric steal syndrome, [16], however, the effect is transient and symptoms generally recur. More importantly, ischemic complications (ischemic cholangitis, ischemic cholecystitis and/or hepatic necrosis) leading to transplant or death occur in approximately 30% of the treated cases, including 50% of treated portal hypertension cases [16]. The 2-year survival with embolization was approximately 73%. The expert panel agreed that the risk of post-embolization ischemia would likely be greatest in patients with biliary presentation of liver VMs. With liver transplantation, symptoms resolved in the majority of patients [17, 18]. Liver transplantation is associated with high blood transfusion requirements, prolonged hospital stay and a relatively high rate of postoperative complications. However, the reported 5-year survival rate of 83% in the larger series [18] compared favorably to overall survival rates for liver transplantation.

**Recommendations**

<table>
<thead>
<tr>
<th>The expert panel recommends that in patients with HHT and abnormal liver enzymes and/or a clinical picture suggestive of complications of liver VMs:</th>
<th>Level of evidence: III</th>
</tr>
</thead>
<tbody>
<tr>
<td>- High output heart failure (exertional dyspnea, orthopnea, edema)</td>
<td>Strength of recommendation: Strong</td>
</tr>
<tr>
<td>- Portal hypertension (variceal hemorrhage, ascites)</td>
<td>Agreement: 83%</td>
</tr>
<tr>
<td>- Biliary (jaundice, fever, abdominal pain)</td>
<td></td>
</tr>
<tr>
<td>- Portosystemic encephalopathy</td>
<td></td>
</tr>
<tr>
<td>- Steal syndrome (intestinal ischemia)</td>
<td></td>
</tr>
</tbody>
</table>

**Doppler US or CT should be offered as a baseline test to confirm liver VMs**

**Clinical Considerations:** The confirmation of the diagnosis of liver VMs in symptomatic patients will help prevent misdiagnosis and allow the clinician to provide appropriate therapy and follow-up. Either Doppler US or CT scan can be used to confirm the diagnosis, though Doppler US is lower risk. In centers where expertise in the interpretation of Doppler US for diagnosis of liver VMs is lacking, triphasic helical CT may be appropriate. Further, more invasive, testing may be performed depending on severity of symptoms and type of clinical presentation. For example, in patients with related heart failure, right heart catheterization with measurement of cardiac index and pulmonary pressures can...
help guide therapy and establish baseline values. In those with symptoms of heart failure versus portal hypertension, hepatic vein catheterization with measurement of hepatic venous pressure gradient can guide therapy. For patients with abdominal pain suggestive of mesenteric ischemia, angiography might clarify the diagnosis.

| To clarify the diagnosis of HHT, the expert panel recommends screening for liver VMs, using Doppler ultrasound, in patients with 1 or 2 HHT diagnostic criteria and in whom genetic testing is either inconclusive or unavailable | Level of evidence: III  
Strength of recommendation: Strong  
Agreement: 78% |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Considerations:</strong> The rationale for recommending screening for liver VMs to clarify the diagnosis of HHT is based on the fact that visceral involvement is one of the diagnostic criteria for HHT, and therefore finding liver VMs in a patient with probable HHT can help further clarify the diagnosis of HHT. When screening is undertaken, it is advisable to screen with the least invasive test, such as Doppler US. Where expertise in Doppler US for liver VMs is lacking, a diagnosis of liver VMs can be made with triphasic CT.</td>
<td></td>
</tr>
</tbody>
</table>
| The expert panel recommends that liver biopsy be avoided in any patient with proven or suspected HHT. | Level of evidence: III  
Strength of recommendation: Strong  
Agreement: 97% |
| **Clinical Considerations:** The rationale for recommending against liver biopsy for diagnosis of liver VMs is that the diagnosis is established with imaging studies whereas biopsy exposes the patient to an unnecessary risk of hemorrhage. |  |
| The expert panel recommends that hepatic artery embolization be avoided in patients with liver VMs as it is only a temporizing procedure associated with significant morbidity and mortality | Level of evidence: III  
Strength of recommendation: Strong  
Agreement: 94% |
| **Clinical Considerations:** Given the elevated risk of post-embolization necrosis, and death this procedure should not be considered as a first-line therapeutic option. It may be reasonable for the clinician to consider hepatic artery embolization in certain patients, such as a patient with heart failure who has failed to respond to optimal medical therapy and who does not have biliary ischemia or portovenous shunting and who is not a transplant candidate. The risks and benefits of embolization and transplant should be considered on an individualized basis, based on type of shunting, clinical syndrome, patient characteristics and patient preference. |  |
The expert panel recommends that referral for liver transplantation be considered in patients with liver VMs that develop:

- Ischemic biliary necrosis
- Intractable heart failure
- Intractable portal hypertension

Clinical Considerations: Since liver transplantation for liver VMs has a good survival rate, it is a reasonable option for patients with severe complications of liver VMs refractory to medical therapy. Patients who develop biliary necrosis have the highest mortality, particularly those who develop it in the setting of heart failure, and therefore should be prioritized for liver transplant, analogous to post-transplant patients that develop bile duct necrosis.

References

Level of evidence: III
Strength of recommendation: Strong
Agreement: 94%


Comments
The HHT Guidelines Working Group intends to generate updated clinical guidelines within approximately five years time.

Centers with recognized expertise in the diagnosis and management of HHT can be located at www.hht.org, the website for the HHT Foundation International.

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article to be published in Journal of Medical Genetics editions and any other BMJPGL products to exploit all subsidiary rights, as set out in their licence http://jmg.bmjjournals.com/ifora/licence.pdf.

All of the authors have contributed to the Guidelines development and the resulting manuscript. None of the authors have any significant competing interests.
**Table 1.** Categorization of the Quality of Evidence

<table>
<thead>
<tr>
<th>Quality of Evidence</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Evidence obtained from at least 1 properly randomized, controlled trial</td>
</tr>
<tr>
<td>II-1</td>
<td>Evidence obtained from well-designed controlled trials without randomization</td>
</tr>
<tr>
<td>II-2</td>
<td>Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than 1 center or research group</td>
</tr>
<tr>
<td>II-3</td>
<td>Evidence obtained from comparison between times and places with or without the intervention, or dramatic results in uncontrolled experiments</td>
</tr>
<tr>
<td>III</td>
<td>Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees</td>
</tr>
</tbody>
</table>
### Table 2. Curaçao Criteria for clinical diagnosis of HHT.

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epistaxis</td>
<td>Spontaneous and recurrent</td>
</tr>
<tr>
<td>Telangiectases</td>
<td>Multiple, at characteristic sites: lips, oral cavity, fingers, nose</td>
</tr>
<tr>
<td>Visceral lesions</td>
<td>GI Telangiectasia, pulmonary, hepatic, cerebral or spinal AVMs</td>
</tr>
<tr>
<td>Family history</td>
<td>A first degree relative with HHT according to these criteria</td>
</tr>
</tbody>
</table>
### Table 3. Level II study of screening tests for PAVMs in HHT patients, using reference standard.

<table>
<thead>
<tr>
<th>Study</th>
<th># subjects</th>
<th>Prevalence PAVMs</th>
<th>Reference Standard</th>
<th>Test</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cottin et al. 2004</td>
<td>105</td>
<td>45%</td>
<td>CT or PA</td>
<td>TTCE</td>
<td>93%</td>
<td>52%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>chest xray</td>
<td>70%</td>
<td>98%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>A-a gradient</td>
<td>68%</td>
<td>98%</td>
</tr>
</tbody>
</table>

A-a gradient=alveolar-arterial gradient calculated from arterial blood gas on room air
CT=computed tomography of the chest
PA=diagnostic pulmonary angiography
TTCE=transthoracic contrast echocardiography (using agitated saline)
Table 4. Level II uncontrolled case series of transcatheter embolization (detachable coils, balloons, etc.) for PAVMs.

<table>
<thead>
<tr>
<th>Study</th>
<th>#subjects/ #PAVMs</th>
<th>Diagnosis of HHT</th>
<th>Mean age (years) (range)</th>
<th>Intervention Done</th>
<th>% with follow-up</th>
<th>Mean follow-up (months)</th>
<th>Outcome post-embolization</th>
<th>Frequency Post-embo Outcome</th>
<th>Procedural Complication</th>
<th>Frequency Complication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pollak et al. 2006</td>
<td>155/415</td>
<td>95%</td>
<td>45 (7-77)</td>
<td>100%</td>
<td>100%</td>
<td>96</td>
<td>PAVM involution</td>
<td>97%</td>
<td>Long-term Pleurisy</td>
<td>0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Reperfusion</td>
<td>3%</td>
<td>Angina</td>
<td>12%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Growth small PAVMs</td>
<td>18%</td>
<td>TIA</td>
<td>2%</td>
</tr>
<tr>
<td>Prasad et al. 2004</td>
<td>54/306</td>
<td>94%</td>
<td>38</td>
<td>100%</td>
<td>100%</td>
<td>35</td>
<td>PAVM involution</td>
<td>93%</td>
<td>Long-term Pleurisy</td>
<td>0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Reperfusion</td>
<td>7%</td>
<td>Paradox embo</td>
<td>12%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Device misplaced</td>
<td></td>
<td>PAVM perforation</td>
<td>&lt;0.5%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TIA</td>
<td></td>
<td>Brain abscess</td>
<td>1%</td>
</tr>
<tr>
<td>Mager et al. 2004</td>
<td>112/296</td>
<td>96%</td>
<td>45 (7-85)</td>
<td>100%</td>
<td>100%</td>
<td>62</td>
<td>Improved PaO2 pre-post</td>
<td>P&lt;0.001</td>
<td>Pleurisy</td>
<td>13%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Improved shunt (100%O2) pre-post</td>
<td>P&lt;0.001</td>
<td>Angina</td>
<td>2%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Reperfusion</td>
<td></td>
<td>Stroke</td>
<td>1%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Growth small PAVMs</td>
<td></td>
<td>TIA</td>
<td>2%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TIA</td>
<td></td>
<td>Brain abscess</td>
<td>1%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Brain abscess</td>
<td></td>
<td>3%</td>
<td>2%</td>
</tr>
<tr>
<td>Study</td>
<td>Patients</td>
<td>Improvement Rate</td>
<td>Post-Operative SpO2</td>
<td>Improved Shunt (\text{Tc} 99 \text{MAA})</td>
<td>Pre-post Improvement of SpO2</td>
<td>Pre-post Improved Shunt (\text{Tc} 99 \text{MAA})</td>
<td>Long-term Complications</td>
<td>3-Month Complications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>----------</td>
<td>------------------</td>
<td>---------------------</td>
<td>------------------------------------------</td>
<td>-----------------------------</td>
<td>------------------------------------------</td>
<td>------------------------</td>
<td>----------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gupta et al. 2002</td>
<td>66/225</td>
<td>83%</td>
<td>44 (13-77)</td>
<td>100%</td>
<td>98%</td>
<td>27</td>
<td>Improved SpO2 pre-post</td>
<td>p&lt;0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>p&lt;0.0001</td>
<td>Long-term Pleurisy</td>
<td>0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Angina</td>
<td>3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Paradox embo</td>
<td>5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hemoptysis</td>
<td>1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dutton et al. 1999</td>
<td>53/--</td>
<td>79%</td>
<td>41 (8-70)</td>
<td>100%</td>
<td>100%</td>
<td>min. 3</td>
<td>Improved SpO2 pre-post</td>
<td>p&lt;0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Improved shunt</td>
<td>p&lt;0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(\text{Tc} 99 \text{MAA})</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Long-term Pleurisy</td>
<td>9%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Angina</td>
<td>3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Confusion</td>
<td>2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Stroke</td>
<td>1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Paradox embo</td>
<td>2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Myocardial puncture</td>
<td>1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lee et al. 1997</td>
<td>45/52</td>
<td>87%</td>
<td>42 (12-73)</td>
<td>100%</td>
<td>100%</td>
<td>56</td>
<td>Reperfusion</td>
<td>15%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Large PAVMs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>31%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pleurisy</td>
<td>2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Air embolism</td>
<td>4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Paradox embolism</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chilvers et al. 1990</td>
<td>15/--</td>
<td>73%</td>
<td>41 (13-63)</td>
<td>100%</td>
<td>100%</td>
<td>3</td>
<td>Improved SpO2 pre-post</td>
<td>P&lt;0.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Improved shunt</td>
<td>P&lt;0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(100%\text{O}2) pre-post</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Improved peak work</td>
<td>60%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>capacity pre-post</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White et al. 1988</td>
<td>76/276</td>
<td>88%</td>
<td>36 (5-76)</td>
<td>100%</td>
<td>95%</td>
<td>min. 3</td>
<td>Tech success</td>
<td>100%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Improved O2 pre-post</td>
<td>77%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TIA</td>
<td>2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pleurisy</td>
<td>5%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Air embolism</td>
<td>3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Paradox embolism</td>
<td>1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DVT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Type</td>
<td>Pregnancy</td>
<td>Tech success</td>
<td>Estimated fetal radiation dose</td>
<td>Pleurisy</td>
<td>Fetal/childhood complications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>-------------</td>
<td>------------</td>
<td>--------------</td>
<td>-------------------------------</td>
<td>----------</td>
<td>------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gershon et al. 2001</td>
<td>Pregnancy</td>
<td>100%</td>
<td>100%</td>
<td>50-220 mRad</td>
<td>100%</td>
<td>50-220 mRad</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>7/13</td>
<td>28 (24-34)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Faughnan et al. 2004</td>
<td>Pediatric</td>
<td>86%</td>
<td>100%</td>
<td>p&lt;0.003</td>
<td>100%</td>
<td>Long-term Pleurisy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>42/172</td>
<td>12 (4-18)</td>
<td>90%</td>
<td>100%</td>
<td>100%</td>
<td>Other pain</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>angina</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Absence of PAVM complix</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(FOCAL group)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Absence of PAVM complix</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(DIFFUSE group)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Reperfusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>83% (2 deaths, 1 from brain abscess, 1 from lung transplant)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>15%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brach plex=brachial plexus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complix=complications</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Embo=embolization</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paradox=paradoxical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulm HTN= Pulmonary hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tc99 MAA=shunt measurement using Technetium 99 labeled albumin macroaggregates</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 5. Therapeutic trials for GI bleeding in HHT.

<table>
<thead>
<tr>
<th>Study</th>
<th>#subjects</th>
<th>% HHT</th>
<th>Mean age (years) (range)</th>
<th>Intervention Done</th>
<th>% follow-up</th>
<th>Mean follow-up (mo.)</th>
<th>Outcome post-treatment</th>
<th>Frequency Post-treatment Outcome</th>
<th>Procedural Complication</th>
<th>Frequency Complication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bown et al. 1985</td>
<td>18, severe GI bleeding, transfusion dependent</td>
<td>8/18 (44%)</td>
<td>62 (42-74)</td>
<td>100% 2 APC 6 ND-YAG (mean 7 sessions)</td>
<td>100%</td>
<td>14</td>
<td>Reduced transfusions No further transfusions Recurrence requiring surgery</td>
<td>8/8 (100%)</td>
<td>Perforation</td>
<td>0%</td>
</tr>
<tr>
<td>Gostout et al. 1988</td>
<td>93, severe GI bleeding, transfusion dependent</td>
<td>10/93 (11%)</td>
<td>63</td>
<td>100% ND-YAG (2-6 sessions)</td>
<td>100%</td>
<td>15</td>
<td>Reduced transfusions</td>
<td>9/10 (90%)</td>
<td>Perforation Delayed bleeding</td>
<td>3/93 (3%) 5/93 (5%)</td>
</tr>
<tr>
<td>Sargeant et al. 1993</td>
<td>41, severe GI bleeding, transfusion dependent</td>
<td>9/41 (22%)</td>
<td>66 (55-81)</td>
<td>100% ND-YAG (repeated sessions)</td>
<td>100%</td>
<td>51</td>
<td>Reduced or stabilized # transfusions Reduction in mean yearly transfusions pre-post</td>
<td>6/9 (67%)</td>
<td>Perforation Antral narrowing</td>
<td>1/41 (2%) 2/41 (4%)</td>
</tr>
<tr>
<td>Van Cutsem et al. 1990</td>
<td>10, severe GI bleeding from VMs, transfusion dependent</td>
<td>6/10 (60%)</td>
<td>65-89</td>
<td>100% ethinylestradiol+ norethisterone vs placebo</td>
<td>100%</td>
<td>6</td>
<td>Reduced mean transfusions pre-post* No further bleeding</td>
<td>p&lt;0.002 5/6</td>
<td>Death (MI) Feminizing Vaginal bleeding</td>
<td>1/10 (10%) 1/10 (10%) 2/10 (20%)</td>
</tr>
<tr>
<td>Longacre et al</td>
<td>43, HHT-</td>
<td>43/43 (100%)</td>
<td>57 (33-78)</td>
<td>23/43 (53%)</td>
<td>100%</td>
<td>18</td>
<td>Mean 8.6 vs 9.9</td>
<td>DVT</td>
<td>1/19 (5%)</td>
<td></td>
</tr>
<tr>
<td>al. 2003</td>
<td>related GI bleeding</td>
<td>medical therapy 19 ethinyl estradiol/norethindrone 2 danacrine 2 aminocaproic acid</td>
<td>hemoglobin pre-post</td>
<td>p=0.0018</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Mean for all 10 patients (HHT and non-HHT)

APC=argon plasma coagulation
Nd-YAG= neodymium-doped yttrium aluminium garnet laser
Table 6. Screening studies for Liver VMs in HHT.

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Population</th>
<th>% HHT</th>
<th>Type of study</th>
<th>Test</th>
<th>Findings for liver VMs</th>
<th>Frequency of abnormality in Liver VMs</th>
<th>Prevalence Liver VMs detected</th>
<th>Gold Standard</th>
</tr>
</thead>
<tbody>
<tr>
<td>Memeo et al. 2005</td>
<td>105</td>
<td>HHT, consecutive patients</td>
<td>100%</td>
<td>Screening</td>
<td>CT</td>
<td>Telangiectasia CVMs</td>
<td>50/78 (64%) 20/78 (26%) 40/78 (51%) 16/78 (21%) 22/78 (28%) 46/78 (59%) 46/78 (59%)</td>
<td>78/100 (78%)</td>
<td>No</td>
</tr>
<tr>
<td>Ravard et al. 2004</td>
<td>24</td>
<td>HHT, consecutive patients</td>
<td>100%</td>
<td>Screening</td>
<td>CT</td>
<td>Dilated HA Telangiectasia AV shunt AP shunt</td>
<td>16/16 (100%) 12/16 (75%) 5/16 (31%) 3/16 (19%)</td>
<td>16/24 (67%)</td>
<td>No</td>
</tr>
<tr>
<td>Buscarini et al. 2004</td>
<td>346</td>
<td>HHT, members of hht families</td>
<td>221 (64%)</td>
<td>Screening</td>
<td>Doppler US</td>
<td>Mild Moderate Severe</td>
<td>11/92 (12%) 70/92 (76%) 11/92 (12%)</td>
<td>92/221 (41%)</td>
<td>No</td>
</tr>
<tr>
<td>Buscarini et al. 1997</td>
<td>73</td>
<td>HHT, one family</td>
<td>40 (55%)</td>
<td>Screening</td>
<td>Doppler US</td>
<td>Mild Moderate Severe</td>
<td>3/13 (23%) 3/13 (23%) 7/13 (46%)</td>
<td>13/40 (32%)</td>
<td>Angio12/13</td>
</tr>
<tr>
<td>Ocran et al. 2004</td>
<td>22</td>
<td>HHT consecutive patients</td>
<td>100%</td>
<td>Screening</td>
<td>Doppler US</td>
<td>Dilated HA Dilated intra HA AV shunts</td>
<td>14/16 (88%) 15/16 (94%) 16/16 (100%)</td>
<td>16/22 (73%)</td>
<td>No</td>
</tr>
</tbody>
</table>

abN=abnormal ;AV=arteriovenous ; CVM=confluent vascular malformations ; HA=hepatic artery ; PHT=portal hypertension ; PV=porto-venous, VM=vascular malformations;  
*4 of 6 in whom the initial diagnosis of HHT was “probable” became definite with the finding of liver VMs  
clinical liver VMs= patients with clinical signs or symptoms of liver VMs
Table 7. Case series of treatment for liver VMs in HHT.

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Clinical types</th>
<th>Treatment</th>
<th>Median follow-up (months)</th>
<th>Outcomes of Treatment</th>
<th>Frequency of Outcomes</th>
<th>Complications</th>
<th>Frequency of Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lerut et al. 2006</td>
<td>40</td>
<td>14 HF, 12 BIL, 5 PHT, 6 HF+BIL, 2 HF+PHT, 1 HF+PHT+BIL</td>
<td>Trans</td>
<td>58</td>
<td>5-year survival</td>
<td>83%</td>
<td>Intraoper bleed†, GI bleed†, CHF†, Acute rejection†, Chronic rejection†, Graft failure†, Cerebral bleed†, PAVM bleed†</td>
<td>1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HF improved</td>
<td>18/24 (75%)</td>
<td>Intraoper bleed†, GI bleed†, CHF†, Acute rejection†, Chronic rejection†, Graft failure†, Cerebral bleed†, PAVM bleed†</td>
<td>1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HF Stable</td>
<td>5/24 (21%)</td>
<td>Intraoper bleed†, GI bleed†, CHF†, Acute rejection†, Chronic rejection†, Graft failure†, Cerebral bleed†, PAVM bleed†</td>
<td>1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HF alone Death</td>
<td>1/24 (4%)</td>
<td>Intraoper bleed†, GI bleed†, CHF†, Acute rejection†, Chronic rejection†, Graft failure†, Cerebral bleed†, PAVM bleed†</td>
<td>1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BIL+/- HF Death</td>
<td>4/18 (22%)</td>
<td>Intraoper bleed†, GI bleed†, CHF†, Acute rejection†, Chronic rejection†, Graft failure†, Cerebral bleed†, PAVM bleed†</td>
<td>1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PHT +/- HF Death</td>
<td>3/8 (38%)</td>
<td>Intraoper bleed†, GI bleed†, CHF†, Acute rejection†, Chronic rejection†, Graft failure†, Cerebral bleed†, PAVM bleed†</td>
<td>1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%) 1/40 (3%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Intraoper bleed†, GI bleed†, CHF†, Acute rejection†, Chronic rejection†, Graft failure†, Cerebral bleed†, PAVM bleed†</td>
<td>24/40 (60%)</td>
</tr>
<tr>
<td>Chavan et al. 2004</td>
<td>15</td>
<td>11 HF, 5 Steal, 4 PHT</td>
<td>Staged HA embo</td>
<td>28</td>
<td>Alive</td>
<td>11/15 (73%)</td>
<td>Hepatic necrosis†, Cholangitis/ cholecystitis†</td>
<td>1/15 (7%) 3/15 (20%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HF alive</td>
<td>10/11 (91%)</td>
<td>Hepatic necrosis†, Cholangitis/ cholecystitis†</td>
<td>1/15 (7%) 3/15 (20%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HF improved</td>
<td>10/11 (91%)</td>
<td>Hepatic necrosis†, Cholangitis/ cholecystitis†</td>
<td>1/15 (7%) 3/15 (20%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Steal alive</td>
<td>5/5 (100%)</td>
<td>Hepatic necrosis†, Cholangitis/ cholecystitis†</td>
<td>1/15 (7%) 3/15 (20%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Steal improved</td>
<td>5/5 (100%)</td>
<td>Hepatic necrosis†, Cholangitis/ cholecystitis†</td>
<td>1/15 (7%) 3/15 (20%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PHT alive</td>
<td>2/4 (50%)</td>
<td>Hepatic necrosis†, Cholangitis/ cholecystitis†</td>
<td>1/15 (7%) 3/15 (20%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PHT improved</td>
<td>2/4 (50%)</td>
<td>Hepatic necrosis†, Cholangitis/ cholecystitis†</td>
<td>1/15 (7%) 3/15 (20%)</td>
</tr>
<tr>
<td>Azoulay et al. 2002</td>
<td>6</td>
<td>3 BIL, 2 PHT, 1 HF+ BIL</td>
<td>Transplant</td>
<td>57</td>
<td>Alive</td>
<td>4/6 (67%)</td>
<td>GI bleeding†, Peritonitis†</td>
<td>1/6 (17%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BIL alive</td>
<td>3/3 (100%)</td>
<td>GI bleeding†, Peritonitis†</td>
<td>1/6 (17%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PHT alive</td>
<td>1/2 (50%)</td>
<td>GI bleeding†, Peritonitis†</td>
<td>1/6 (17%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HF+BIL alive</td>
<td>0/1 (0%)</td>
<td>GI bleeding†, Peritonitis†</td>
<td>1/6 (17%)</td>
</tr>
</tbody>
</table>

*HA= hepatic artery, HF=high output heart failure; PHT=portal hypertension; BIL=biliary
†Causing death
Acknowledgements
Many thanks to the following people who contributed at different stages to the HHT Guidelines: Marianne Clancy MPA, Justine Cohen-Silver MD MSc, Sharon Straus MD MSc, Dave Davis MD, Mary Ellyn Parker RN, Ana Carvalho, Joyce Fenuta RN BScN MHS, Beth Plahn RN MHA, David Stoner BS RPh, Keith Williams, Cheryl Wilson MA MS, Jane E. Tumpson MAT MBA, Samir Gupta MD MSc, Kevin Sanders MD MSc, Anna R. Gagliardi PhD, Andrew Worster MD and Denice Feig MD MSc.

Funding
Funding Sources: John Abele on behalf of the Argosy Foundation, HHT Foundation International Inc., Canadian Institutes of Health Research, St Michael's Hospital Department of Medicine

Financial support (M.E.F.): Nelson Arthur Hyland Foundation, Li Ka Shing Knowledge Institute of St. Michael’s Hospital
Appendix I. Background Literature Review

We utilized the database OVID medline and searched for articles between the dates of 1966 to present. We used related MESH headings, then exploded search, and also included all related terms/spellings as “keywords”.

<table>
<thead>
<tr>
<th>Topic</th>
<th>MESH and Key Words</th>
<th>Inclusion Criteria for Diagnostic Evidence Table</th>
<th>Inclusion Criteria for Treatment Evidence Table</th>
</tr>
</thead>
</table>
| HHT Diagnosis  | Telangiectasia, hereditary hemorrhagic Rendu-Osler-Weber| English language  
Human studies  
N>5  
Articles required the following information:  
1) Results including sensitivity and specificity of diagnostic tests  OR  
2) Raw data which would allow for calculation of sensitivity and specificity of diagnostic tests. | Not applicable                                                                     |
|                | HHT  
Arteriovenous malformations AND  
Mutation  
SMAD4  
Endoglin, ENG  
Activin Receptor, type I  
ALK1  
ACVRL1  
HHT1  
HHT2 |                                                                 |                                                                                                             |
| Epistaxis      | Telangiectasia, hereditary hemorrhagic Rendu-Osler-Weber| English language  
Human studies  
N>5  
Articles required the following information:  
1) Results including sensitivity and specificity of diagnostic tests  OR  
2) Raw data which would allow for calculation of sensitivity and specificity of diagnostic tests. | English language  
Human studies  
N>5  

**Exclusion:**  
Review articles or Comment articles without raw data  
No treatment outcomes reported  
Study patients not sufficiently described |
|                | HHT  
Epistaxis  
Nosebleed  
Laser  
Cryotherapy  
Septal dermoplasty  
Young’s procedure  
Embolization  
Cautery or electrocoagulation  
Hormones or hormone therapy  
Aminocaproic acid  
Tranexamic acid |                                                                 |                                                                                             |
| CVMs | Arteriovenous malformation  
CAVM  
Cerebral arteriovenous malformation  
Brain arteriovenous malformation  
Intracranial arteriovenous malformations/ or exp central nervous system vascular malformations  
Sensitivity and specificity  
Randomized Controlled Trials  
Case-Control Studies  
Clinical Trials | English language  
Human studies  
N>5  
Articles required the following information:  
1) Results including sensitivity and specificity of diagnostic tests OR  
2) Raw data which would allow for calculation of sensitivity and specificity of diagnostic tests. | English language  
Human studies  
N>200  
Exclusion:  
Review articles or Comment articles without raw data  
No treatment outcomes reported  
Study patients not sufficiently described |
|---|---|---|
| PAVMs | Telangiectasia, hereditary hemorrhagic  
Rendu-Osler-Weber HHT  
Pulmonary arteriovenous malformation  
Lung arteriovenous malformation  
PAVM | English language  
Human studies  
N>5  
Articles required the following information:  
1) Results including sensitivity and specificity of diagnostic tests OR  
2) Raw data which would allow for calculation of sensitivity and specificity of diagnostic tests. | English language  
Human studies  
N>5  
Exclusion:  
Review articles or Comment articles without raw data  
No treatment outcomes reported  
Study patients not sufficiently described |
| GI Bleeding | Telangiectasia, hereditary hemorrhagic  
Rendu-Osler-Weber HHT  
Gastrointestinal arteriovenous malformation  
Gastrointestinal tract/intestinal/ lower gastrointestinal tract | English language  
Human studies  
N>5  
Articles required the following information:  
1) Results including sensitivity and specificity of diagnostic tests OR  
2) Raw data which would allow for calculation of sensitivity and specificity of diagnostic tests. | English language  
Human studies  
N>5  
Exclusion:  
Review articles or Comment articles without raw data  
No treatment outcomes reported  
Study patients not sufficiently described |
| LVMs | Telangiectasia, hereditary hemorrhagic  
Rendu-Osler-Weber HHT  
AND | English language  
Human studies  
N>5  
Articles required the following information: | English language  
Human studies  
N>5 |
<table>
<thead>
<tr>
<th>Liver arteriovenous malformation</th>
<th>1) Results including sensitivity and specificity of diagnostic tests OR 2) Raw data which would allow for calculation of sensitivity and specificity of diagnostic tests</th>
<th>Exclusion: Review articles or Comment articles without raw data No treatment outcomes reported Study patients not sufficiently described</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatic arteriovenous malformation</td>
<td>Liver/bile ducts, intrahepatic/intrahepatic/hepatic</td>
<td></td>
</tr>
</tbody>
</table>
### Appendix II. Future research priorities for HHT in general and each Topic.

<table>
<thead>
<tr>
<th>Topic</th>
<th>Future Research Priorities</th>
</tr>
</thead>
</table>
| **General** | • Improve quality of evidence in all areas of diagnosis and treatment of HHT  
• Better define natural history of HHT by developing multicenter collaborative database  
• Study implementation and knowledge translation of practice guidelines in rare disease  
• Revise guidelines regularly, as diagnostic technology improves, new treatments become available and evidence improves  
• Further develop and validate Quality of Life instruments in HHT, and include these as study outcomes |
| **Diagnosis** | • Determine sensitivity and specificity of Curacao Criteria in different age groups  
• Better identify natural history of HHT  
• Further identify prevalence of SMAD4 mutation in HHT and phenotype with SMAD4 mutation  
• Identify the two additional suspected HHT genes  
• Study uptake of recommendations for children  
• Assess quality of life impact of early HHT diagnosis |
| **Epistaxis** | • Develop and validate a patient-based outcome instrument, which incorporates both subjective (i.e., physical symptoms, functional limitations, and emotional/social limitations) and objective (i.e., severity of anemia, need for transfusion) parameters, for measurement of epistaxis (high priority)  
• Develop and study novel therapies for telangiectasia, for example, antiangiogenic therapy, etc. |
| **CVMs** | • Better define natural history of CVMs in HHT, through multicenter collaborative database  
• Define morphology of CVMs in HHT and relationship to clinical outcomes, through multicenter collaborative data collection  
• Study treatment options for CVMs in HHT, through multicenter collaborative research |
| **PAVMs** | • Determine accuracy and safety for screening tests for PAVMs in children  
• Study outcomes of long-term re-screening for PAVMs in order to establish appropriate screening interval  
• Determine natural history of patients with suspected microscopic PAVMs (positive TTCE but no PAVMs detectable on CT)  
• Study use of other contrast agents, for TTCE, than agitated saline  
• Collect better safety data about TTCE in this population |
| **GI Bleeding** | • Evaluate and compare traditional and novel therapies for GI bleeding in HHT in multicenter collaborative studies |
| **Liver VMs** | • Determine appropriate timing and indications for liver transplantation  
• Development and study of novel therapies for liver VMs, for example, antiangiogenic therapy, etc. |
Figure. The adopted process of guideline development

Development of Guidelines Process
AGREE instrument used for framework.
Organizing committee formed.

Determination of Need for Guidelines
Consultation with HHT foundation International.
Consultation with HHT experts.
Review of literature.

Membership of Guidelines Working Group
Identification of experts in all related areas.
Inclusion of other relevant stakeholders and patients.

Determination of Clinically Relevant Questions
Working group identified key questions.

Background Preparation
Identified key articles through literature search.
Working group reviewed evidence tables.
Drafted pre-conference recommendations.

Preparation of Report
Topic leaders prepared topic reports.
Draft manuscript circulated for working group review.

Guidelines Conference
Presented and discussed recommendations.
Grading and voting of recommendations.
International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia

J Med Genet  published online June 23, 2009

Updated information and services can be found at:
http://jmg.bmj.com/content/early/2009/06/29/jmg.2009.069013

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Open access (170)
Epidemiology (625)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/